[go: up one dir, main page]

WO2003059352A3 - Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires - Google Patents

Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires Download PDF

Info

Publication number
WO2003059352A3
WO2003059352A3 PCT/FR2003/000107 FR0300107W WO03059352A3 WO 2003059352 A3 WO2003059352 A3 WO 2003059352A3 FR 0300107 W FR0300107 W FR 0300107W WO 03059352 A3 WO03059352 A3 WO 03059352A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
treatment
parasitic diseases
novel class
parasitic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2003/000107
Other languages
English (en)
Other versions
WO2003059352B1 (fr
WO2003059352A2 (fr
Inventor
Stanislas Tomavo
Florence Dzierszinski
Alexandra Coppin
Bels Frederic De
Jean-Claude Ameisen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to AU2003214317A priority Critical patent/AU2003214317A1/en
Publication of WO2003059352A2 publication Critical patent/WO2003059352A2/fr
Publication of WO2003059352A3 publication Critical patent/WO2003059352A3/fr
Publication of WO2003059352B1 publication Critical patent/WO2003059352B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention se rapporte à l'utilisation d'au moins une molécule ligand du récepteur périphérique des benzodiazépines (PBR) pour la fabrication de médicaments destinés au traitement de maladies parasitaires. Plus particulièrement, il s’agit de dérivés de la 1-phényle, 3-aminocarbonyle-isoquinoline et de la 5-phényle-1, 4-benzodiazepine. L’invention inclut un procédé de criblage de molécules à activité anti-parasitaire utilisant le récepteur périphérique de benzodiazépines.
PCT/FR2003/000107 2002-01-15 2003-01-14 Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires Ceased WO2003059352A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003214317A AU2003214317A1 (en) 2002-01-15 2003-01-14 Use of a novel class of drugs for the treatment of parasitic diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR02/00439 2002-01-15
FR0200439A FR2834637A1 (fr) 2002-01-15 2002-01-15 Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires

Publications (3)

Publication Number Publication Date
WO2003059352A2 WO2003059352A2 (fr) 2003-07-24
WO2003059352A3 true WO2003059352A3 (fr) 2004-03-11
WO2003059352B1 WO2003059352B1 (fr) 2004-04-15

Family

ID=8871295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2003/000107 Ceased WO2003059352A2 (fr) 2002-01-15 2003-01-14 Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires

Country Status (3)

Country Link
AU (1) AU2003214317A1 (fr)
FR (1) FR2834637A1 (fr)
WO (1) WO2003059352A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894478B1 (fr) * 2005-12-08 2008-06-06 Anticiper Et Developper L Inno Application de l'isoquinoline carboxamide et de ses derives en tant qu'inhibiteurs de virulence bacterienne en remplacement ou en complement des antibiotiques classiques
WO2007088528A1 (fr) * 2006-02-03 2007-08-09 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin Agents de ciblage de microtubules
GB0907284D0 (en) 2009-04-28 2009-06-10 Queen Mary & Westfield College Compounds for inducing cellular apoptosis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046890A (en) * 1974-06-28 1977-09-06 Hoffmann-La Roche Inc. Benzodiazepine derivatives
US5182387A (en) * 1991-10-30 1993-01-26 Merrell Dow Pharmaceuticals Inc. Bis-dibenzoazepine compounds
WO2001051922A2 (fr) * 2000-01-14 2001-07-19 Mitokor Procedes pour identifier les agents liant le recepteur de benzodiazepine peripherique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046890A (en) * 1974-06-28 1977-09-06 Hoffmann-La Roche Inc. Benzodiazepine derivatives
US5182387A (en) * 1991-10-30 1993-01-26 Merrell Dow Pharmaceuticals Inc. Bis-dibenzoazepine compounds
WO2001051922A2 (fr) * 2000-01-14 2001-07-19 Mitokor Procedes pour identifier les agents liant le recepteur de benzodiazepine peripherique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BENNETT J L: "CHARACTERISTICS OF ANTI SCHISTOSOMAL BENZODIAZEPINE BINDING SITES IN SCHISTOSOMA-MANSONI", JOURNAL OF PARASITOLOGY, vol. 66, no. 5, 1980, pages 742 - 747, XP008006844, ISSN: 0022-3395 *
DE CARNERI, IVO: "Drug sensitivity of Hartmannella and Naegleria causative agents of meningoencephalitis", RIV. PARASSITOL. (1970), 31(1), 1-8, XP008006854 *
DZIERSZINSKI, FLORENCE ET AL: "Ligands of the peripheral benzodiazepine receptor are potent inhibitors of Plasmodium falciparum and Toxoplasma gondii in vitro", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY ( 2002 ), 46(10), 3197-3207, XP002239758 *
ESTAMBALE, B. B. A. ET AL: "The efficacy of 22,23-dihydroavermectin B1 (Ivermectin) acting singly or in combination with a benzodiazepine on microfilariae of Onchocerca species and Brugia pahangi (an in vitro study)", ZENTRALBL. BAKTERIOL. (1989), 271(2), 249-55, XP008006852 *
GELLRICH SYLKE ET AL: "In vitro effects of benzodiazepines against Leishmania mexicana amazoniensis and Trypanosoma cruzi.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 104, no. 4, 1995, Annual Meeting of the Society for Investigative Dermatology;Chicago, Illinois, USA; May 24-28, 1995, pages 686, XP008006846, ISSN: 0022-202X *
NEAL, R. A. ET AL: "In vitro anti-leishmanial activity of compounds in current clinical use for unrelated diseases", DRUGS EXP. CLIN. RES. (1988), 14(10), 621-8, XP008005467 *
PAX R ET AL: "A BENZODIAZEPINE DERIVATIVE AND PRAZIQUANTEL EFFECTS ON MUSCULATURE OF SCHISTOSOMA-MANSONI AND SCHISTOSOMA-JAPONICUM", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, vol. 304, no. 3, 1978, EN, pages 309 - 316, XP008006838, ISSN: 0028-1298 *
ZUCCOTTO, F. ET AL: "Novel inhibitors of Trypanosoma cruzi dihydrofolate reductase", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2001), 36(5), 395-405, XP004254750 *

Also Published As

Publication number Publication date
FR2834637A1 (fr) 2003-07-18
AU2003214317A1 (en) 2003-07-30
WO2003059352B1 (fr) 2004-04-15
WO2003059352A2 (fr) 2003-07-24

Similar Documents

Publication Publication Date Title
AP2005003232A0 (en) Combination therapy for hyperproliferative diseases.
NO20053384L (no) Benzazepinderivater for behandling av neurologiske forstyrrelser.
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
WO2005046603A3 (fr) Composes pyridiniques
DE60322865D1 (de) Verbindungen mit einzigartiger cb1-rezeptor-bindungsselektivität und herstellungs- und anwendungsverfahren dafür
AU2003301957A1 (en) Administration of anti-inflammatory drugs into the central nervous system
NO20053150D0 (no) System for administrasjon av medisin.
AU2003278119A1 (en) Bicyclic benzamide compounds as histamine h3 receptor ligand useful in the treatment of neurological diseases
AU2003211238A1 (en) Drug delivery system for the subconjunctival administration of fine grains
EP1449542A4 (fr) Preparations medicinales contenant du materiel genetique destinees au traitement de maladies neurodegeneratives
WO2000067847A3 (fr) Utilisation de ligands du recepteur de la dopamine d3 pour la production de medicaments servant au traitement de dysfonctionnements renaux
WO2005023833A3 (fr) Traitement de maladies neurodegeneratives
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2002348746A1 (en) A herbal molecule as potential anti-leukemic drug
AU2003224002A1 (en) Drugs for the arthritis treatment
WO2004064757A3 (fr) Agents facilitant l'absorption
WO2003059352A3 (fr) Utilisation d'une nouvelle classe de medicaments pour le traitement de maladies parasitaires
MA27418A1 (fr) Ensemble de distribution de medicament.
AU2002358469A1 (en) Modified receptors for the discovery of therapeutic ligands
WO2005092062A3 (fr) Composes destines aux troubles neurodegeneratifs
AU2003242338A1 (en) Medicine trial production supporting system
EP1532987A4 (fr) Agents therapeutique genique pour troubles cerebrovasculaires
AU2003211940A1 (en) Drugs for mitochondrial diseases
ZA200407358B (en) Microorganism for genetic therapeutic treatment ofproliferative diseases.
AU2003227191A1 (en) Remedies for protozoan diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
B Later publication of amended claims

Effective date: 20030930

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP